[go: up one dir, main page]

NO20052244L - Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav - Google Patents

Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav

Info

Publication number
NO20052244L
NO20052244L NO20052244A NO20052244A NO20052244L NO 20052244 L NO20052244 L NO 20052244L NO 20052244 A NO20052244 A NO 20052244A NO 20052244 A NO20052244 A NO 20052244A NO 20052244 L NO20052244 L NO 20052244L
Authority
NO
Norway
Prior art keywords
hydroxy
crystal forms
carboxamide
enantiomers
dihydro
Prior art date
Application number
NO20052244A
Other languages
English (en)
Other versions
NO20052244D0 (no
Inventor
Gottfried Sedelmeier
Sabine Pfeffer
Fritz Blatter
Christian Mathes
Dominique Grimler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20052244D0 publication Critical patent/NO20052244D0/no
Publication of NO20052244L publication Critical patent/NO20052244L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Oppfinnelsen vedrører en ny fremgangsmåte for fremstilling av substituerte enantiorene 10-hydroksy-dihydrodiberu[b,f]a2epiner HO (la), R (lb) der hver av r' og R", uavhengig av hverandre, er hydrogen, halogen, amino eller nitro; og hver av R" og R"*, uavhengig av hverandre, er hydrogen eller Ci-C6alkyl; ved overføringshydrogcnering av 10-okso-dihydrodibenz[b,flazepiner; og nye katalysatorer med formel in'a og Iirb 04.0 ' M H 04.0 ,N pa (lira), L,^^.N ,r: / \ 8 (iirb) N¿C der M is Ru, Rh, Ir, Fe, Co eller Ni; Li er hydrogen; L: står for en aryl eller aryl-alifatisk rest; og de ytterligere radikalene har betydningene som her er definert; og nye kry,<;tallformer av begge enantiomerene av 10.1 l-dihydro-10-hydroksy-5H- dibcnz[h,f]a7.epin-5-karboksamid, som kan fremstilles ved de nye fremgangsmåtene, deres anvendelse ved fremstilling av farmasoytiske preparater, nye 1'amiasøytiske preparater som omfatter disse nye krystallformene og'eller anvendelse av disse nye krystallformene \ed behandling av forstyrrelser slik som epilepsi, eller ved fremstilling av farmasoytiske formuleringer som er egnet for denne behandlingen.
NO20052244A 2002-10-07 2005-05-06 Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav NO20052244L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223224.7A GB0223224D0 (en) 2002-10-07 2002-10-07 Organic compounds
PCT/EP2003/011034 WO2004031155A1 (en) 2002-10-07 2003-10-06 ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF

Publications (2)

Publication Number Publication Date
NO20052244D0 NO20052244D0 (no) 2005-05-06
NO20052244L true NO20052244L (no) 2005-07-07

Family

ID=9945425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052244A NO20052244L (no) 2002-10-07 2005-05-06 Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav

Country Status (20)

Country Link
US (1) US20060142566A1 (no)
EP (1) EP1551808A1 (no)
JP (1) JP2006504710A (no)
KR (1) KR20050071549A (no)
CN (2) CN101062932A (no)
AR (1) AR041544A1 (no)
AU (1) AU2003276055B2 (no)
BR (1) BR0315113A (no)
CA (1) CA2501237A1 (no)
EC (1) ECSP055738A (no)
GB (1) GB0223224D0 (no)
HK (1) HK1079790A1 (no)
MX (1) MXPA05003737A (no)
NO (1) NO20052244L (no)
PE (1) PE20040686A1 (no)
PL (1) PL376379A1 (no)
RU (1) RU2005114350A (no)
TW (1) TW200413324A (no)
WO (1) WO2004031155A1 (no)
ZA (1) ZA200502561B (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303615D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
GB0425320D0 (en) 2004-11-17 2004-12-22 Johnson Matthey Plc Diamines
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0515690D0 (en) * 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
GB2437078A (en) 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
JP5172124B2 (ja) * 2006-09-29 2013-03-27 関東化学株式会社 ２位に置換基を有する光学活性キヌクリジノール類の製造方法
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2011045648A2 (en) * 2009-10-12 2011-04-21 Matrix Laboratories Limited Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof
EP2383261B1 (en) 2010-04-23 2013-09-04 Euticals GmbH Process for the asymmetric hydrogenation of ketones
CN102250005B (zh) * 2010-05-19 2015-04-08 浙江九洲药物科技有限公司 艾利西平的制备方法
ES2687678T3 (es) 2011-03-08 2018-10-26 Jubilant Life Sciences Limited Procedimiento para la preparación de (S)-(+)-10,11-dihidro-10-hidroxi-5H-dibenzo[b,f]azepina-5-carboxamida y ésteres de la misma mediante reducción enantioselectiva de 10,11-dihidro-10-oxo-5H-dibenzo[b,f]azepina-5-carboxamida
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
EP2847158A4 (en) 2012-05-07 2015-12-30 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
JP6202287B2 (ja) 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド 炎症性腸疾患の治療のための組成物及び方法
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US20150232426A1 (en) 2012-09-26 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
EP3016961B1 (en) * 2013-07-01 2017-11-15 Boehringer Ingelheim International GmbH Novel ruthenium catalysts and their use for asymmetric reduction of ketones
CN103483257A (zh) * 2013-09-06 2014-01-01 江苏同禾药业有限公司 一种亚氨基芪的合成方法
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
EP3064490A1 (en) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate
CN107033079B (zh) * 2016-10-17 2020-07-28 扬子江药业集团北京海燕药业有限公司 醋酸艾司利卡西平的制备方法
CN112679433B (zh) * 2019-10-18 2024-05-24 浙江九洲药业股份有限公司 一种艾利西平的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
JP2003502296A (ja) * 1999-06-15 2003-01-21 ロディア・シミ スルホニルアミド及びカルボキサミド並びに不斉触媒作用におけるそれらの使用
WO2002064557A2 (en) * 2001-02-12 2002-08-22 Teva Pharmaceutical Industries Ltd. New crystal forms of oxcarbazepine and processes for their preparation

Also Published As

Publication number Publication date
ZA200502561B (en) 2006-02-22
CN101062932A (zh) 2007-10-31
AU2003276055B2 (en) 2008-01-03
TW200413324A (en) 2004-08-01
EP1551808A1 (en) 2005-07-13
MXPA05003737A (es) 2005-06-17
PL376379A1 (en) 2005-12-27
US20060142566A1 (en) 2006-06-29
BR0315113A (pt) 2005-08-23
HK1079790A1 (zh) 2006-04-13
WO2004031155A1 (en) 2004-04-15
ECSP055738A (es) 2005-07-06
KR20050071549A (ko) 2005-07-07
AR041544A1 (es) 2005-05-18
PE20040686A1 (es) 2004-10-29
CA2501237A1 (en) 2004-04-15
AU2003276055A1 (en) 2004-04-23
NO20052244D0 (no) 2005-05-06
RU2005114350A (ru) 2006-01-20
CN1703404A (zh) 2005-11-30
GB0223224D0 (en) 2002-11-13
JP2006504710A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
NO20052244L (no) Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav
ES2674747T3 (es) Inhibidores de demetilasa LSD1 basados en arilciclopropilamina y sus usos médicos
EP2598480B1 (en) Cyclopropylamine derivatives useful as lsd1 inhibitors
TWI868528B (zh) Ｔｙｋ２抑制劑之生產方法
MY148558A (en) Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
MX2009012608A (es) Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso.
Tashima et al. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
MX2012010658A (es) Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
AR040489A1 (es) Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen
CA3150492A1 (en) USP30 INHIBITORS AND USES THEREOF
Taha et al. Synthesis of potent urease inhibitors based on disulfide scaffold and their molecular docking studies
JP2016525142A (ja) １，７−ナフチリジン誘導体
DE502005010342D1 (en) Substituierte cyclohexylessigsäure-derivate
WO2023183908A1 (en) Tyk2 inhibitor synthesis and intermediates thereof
EP4305021A1 (en) Usp30 inhibitors and uses thereof
NO20064752L (no) N-piperidinderivater som CCR3-modulatorer
BR112019015886A2 (pt) Processos enzimáticos para a preparação de ácido (±)-2-(difluorometil)-1-(alcoxicarbonil)-ciclopropanocarboxílico e (±)-ácido 2-(vinil)-1-(alcoxicarbonil)-ciclopropanocarboxílico
ATE283838T1 (de) Wirksame derivate der valproinsäure zur behandlung von neurologischen und psychotischen störungen, und ein verfahren zu ihrer herstellung
KR20130141505A (ko) (6ｒ)-테트라하이드로비옵테린 하이드로클로라이드의 제조 방법
CN109890798A (zh) 用于治疗cns病症的羟基去甲氯胺酮衍生物
Ramudua et al. Synthesis, spectral characterization and bioactivity evaluation of sulfonamide derivatives of p-nitrobenzene sulfonylchloride
WO2015129603A1 (ja) 活性化血液凝固第Ｘ因子（ＦＸａ）阻害剤の高純度結晶
PL1761480T3 (pl) Inhibitory mao-b
TWI481612B (zh) （６ｒ）－四氫生物喋呤鹽酸鹽的製備方法

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application